

Methitest (methyltestosterone tablet)
methyltestosterone capsule
Natesto (testosterone nasal gel)
Striant (testosterone buccal system)
Jatenzo, Kyzatrex, Tlando* (testosterone undecanoate capsule)

*Non-covered medications must go through prior authorization and the formulary exception

Pre - PA Allowance

None

Prior-Approval Requirements

Age 12 years of age or older

Gender Male

Methitest and methyltestosterone capsule ONLY

Diagnosis

Patient must have the following:

Delay in sexual development and/or puberty

a. **NO** dual therapy with another testosterone product

AND confirmation that the following will be monitored every 6 months:

- 1. Assessment of bone age of the hand and wrist (as determined by radiographic evidence)
- 2. Liver function tests
- 3. Hematocrit levels

Age 18 years of age or older

Gender Female only

Methitest and methyltestosterone capsule ONLY

Diagnosis

Patient must have the following:

- 1. Inoperable metastatic breast or mammary cancer
- 2. The patient has received at least one prior therapy



Methitest (methyltestosterone tablet)
methyltestosterone capsule
Natesto (testosterone nasal gel)
Striant (testosterone buccal system)
Jatenzo, Kyzatrex, Tlando* (testosterone undecanoate capsule)

*Non-covered medications must go through prior authorization and the formulary exception

3. **NO** dual therapy with another testosterone product

AND confirmation that the following will be monitored every 6 months:

- a. Hypercalcemia and agreement to discontinue the drug if present
- b. Liver function tests
- c. Hematocrit level

Age 18 years of age or older

Gender Male

Diagnosis

Patient must have the following:

Deficiency of testosterone (hypogonadism)

AND ALL of the following:

- 1. Two morning total testosterone levels less than 300 ng/dL on different days
- 2. Patients over 40 years of age must have baseline PSA less than 4 ng/ml
 - a. Prostatectomy patients excluded from the requirement
- 3. Absence of current prostate cancer / palpable prostate nodules
- 4. Hematocrit less than 54%
- 5. Patients with concurrent diagnosis of benign prostatic hypertrophy (BPH) **ONLY**: patient will be monitored for worsening of BPH symptoms
- 6. Evaluation of cardiovascular risk for myocardial infarction (MI), angina, stroke
- 7. Absence of untreated sleep apnea
- 8. **NO** dual therapy with another testosterone product

AND NONE of the following (Natesto **ONLY**):

1. Chronic nasal conditions or alterations in nasal anatomy



Methitest (methyltestosterone tablet)
methyltestosterone capsule
Natesto (testosterone nasal gel)
Striant (testosterone buccal system)
Jatenzo, Kyzatrex, Tlando* (testosterone undecanoate capsule)

*Non-covered medications must go through prior authorization and the formulary exception

Diagnosis

Patient must have the following:

Gender Dysphoria (GD)

- 1. Female to male transition
- 2. NO dual therapy with another testosterone product

Prior - Approval Limits

| Oral Testosterone | Gender | Quantity | Days Supply |
|----------------------------|-------------------------|------------------------------|----------------|
| Methitest | Male | 450 tablets | 90 |
| | Female | 1800 tablets | 90 |
| methyltestosterone capsule | Male | 450 capsules | 90 |
| | Female | 1800 capsules | 90 |
| latana | Male | 158 mg = 360 capsules | 90 |
| | | 198 mg = 360 capsules | 90 |
| | (adult only) | 237 mg = 180 capsules | 90 |
| Jatenzo | Famala | 158 mg = 360 capsules | 90 |
| | Female (for GD only) | 198 mg = 360 capsules | 90 |
| | | 237 mg = 180 capsules | 90 |
| Kyzatrex | Male (adult only) | 360 capsules | 90 |
| | Female (for GD only) | 360 capsules | 90 |
| Natesto nasal gel | Male (adult only) | 66 grams (9 bottles) | 90 |
| | Female (for GD only) | 66 grams (9 bottles) | 90 |
| Striant buccal system | Male (adult only) | 180 buccal systems (3 boxes) | 90 |
| | Female (for GD only) | 180 buccal systems (3 boxes) | 90 |

| Oral Testosterone with Gender | Quantit | ty Days |
|-------------------------------|---------|---------|
|-------------------------------|---------|---------|



Methitest (methyltestosterone tablet)
methyltestosterone capsule
Natesto (testosterone nasal gel)
Striant (testosterone buccal system)
Jatenzo, Kyzatrex, Tlando* (testosterone undecanoate capsule)

*Non-covered medications must go through prior authorization and the formulary exception

| approved FE only | | | Supply |
|------------------|-------------------------|--------------|--------|
| Tlando | Male (adult only) | 360 capsules | 90 |
| | Female (for GD only) | 360 capsules | 90 |

Duration 6 months for all diagnoses except GD

2 years for GD (age ≥ 19 years)

Until end of plan year for GD (age < 19 years)

Prior - Approval Renewal Requirements

Age 12 years of age or older

Gender Male

Methitest and methyltestosterone capsule ONLY

Diagnosis

Patient must have the following:

Delay in sexual development and/or puberty

a. NO dual therapy with another testosterone product

AND confirmation that the following will be monitored every 6 months:

- 1. Assess bone age of the hand and wrist (as determined by radiographic evidence)
- 2. Liver function tests
- 3. Hematocrit levels

Age 18 years of age or older

Gender Female only



Methitest (methyltestosterone tablet)
methyltestosterone capsule
Natesto (testosterone nasal gel)
Striant (testosterone buccal system)
Jatenzo, Kyzatrex, Tlando* (testosterone undecanoate capsule)

Methitest and methyltestosterone capsule **ONLY**

Diagnosis

Patient must have the following:

- 1. Inoperable metastatic breast or mammary cancer
- 2. The patient has received at least one prior therapy
- 3. **NO** dual therapy with another testosterone product

AND confirmation that the following will be monitored every 6 months:

- a. Hypercalcemia and agreement to discontinue the drug if present
- b. Liver function tests
- c. Hematocrit level

Age 18 years of age or older

Gender Male

Diagnosis

Patient must have the following:

Deficiency of testosterone (hypogonadism)

AND ALL of the following:

- 1. Total testosterone levels of 800 ng/dL or less
- 2. Patients with concurrent diagnosis of benign prostatic hypertrophy (BPH) **ONLY**: absence of worsening of BPH symptoms
- 3. Re-evaluation of cardiovascular risk for MI, angina, stroke
- 4. **NO** dual therapy with another testosterone product

AND confirmation that the following are being monitored every 12 months:

1. Serum testosterone concentrations

^{*}Non-covered medications must go through prior authorization and the formulary exception



Methitest (methyltestosterone tablet)
methyltestosterone capsule
Natesto (testosterone nasal gel)
Striant (testosterone buccal system)
Jatenzo, Kyzatrex, Tlando* (testosterone undecanoate capsule)

*Non-covered medications must go through prior authorization and the formulary exception

- 2. Prostate specific antigen (PSA) for patients over 40 years of age
 - a. Prostatectomy patients excluded from the requirement
- 3. Hematocrit levels

Diagnosis

Patient must have the following:

Gender Dysphoria (GD)

- 1. Female to male transition
- 2. **NO** dual therapy with another testosterone product

Prior Approval Renewal Limits

| Oral Testosterone | Gender | Quantity | Days Supply |
|----------------------------|-------------------------|------------------------------|----------------|
| Methitest | Male | 450 tablets | 90 |
| | Female | 1800 tablets | 90 |
| methyltestosterone capsule | Male | 450 capsules | 90 |
| · | Female | 1800 capsules | 90 |
| | Male (adult only) | 158 mg = 360 capsules | 90 |
| | | 198 mg = 360 capsules | 90 |
| latanza | | 237 mg = 180 capsules | 90 |
| Jatenzo | Female (for GD only) | 158 mg = 360 capsules | 90 |
| | | 198 mg = 360 capsules | 90 |
| | | 237 mg = 180 capsules | 90 |
| Kyzatrex | Male (adult only) | 360 capsules | 90 |
| | Female (for GD only) | 360 capsules | 90 |
| Natesto nasal gel | Male (adult only) | 66 grams (9 bottles) | 90 |
| | Female (for GD only) | 66 grams (9 bottles) | 90 |
| Striant buccal system | Male (adult only) | 180 buccal systems (3 boxes) | 90 |



Methitest (methyltestosterone tablet)
methyltestosterone capsule
Natesto (testosterone nasal gel)
Striant (testosterone buccal system)
Jatenzo, Kyzatrex, Tlando* (testosterone undecanoate capsule)

*Non-covered medications must go through prior authorization and the formulary exception

| Female | 180 buccal systems (3 | 90 |
|---------------|-----------------------|----|
| (for GD only) | boxes) | |

| Oral Testosterone with approved FE only | Gender | Quantity | Days Supply |
|--|-------------------------|--------------|----------------|
| Tlando | Male (adult only) | 360 capsules | 90 |
| | Female (for GD only) | 360 capsules | 90 |

Duration 12 months for all diagnoses except GD

2 years for GD (age ≥ 19 years)

Until end of plan year for GD (age < 19 years)